click on circles to display study description...

STOP-COVID (Guimarães), 2021 NCT04469114

tofacitinib (n=144) vs. placebo (n=145)

randomized controlled trial

tofacitinib at a dose of 10 mg twice daily
for up to 14 days or until hospital discharge

placebo

COVID 19 hospitalized

patients 18 years of age or older who had laboratory-confirmed SARS-CoV-2 infection as determined on RT-PCR assay before randomization, who had evidence of Covid-19 pneumonia on radiographic imaging, and who had been hospitalized for less than 72 hours.The main exclusion criteria were the use of noninvasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) on the day of randomization, a history of thrombosis or current thrombosis, known immunosuppression, and any current cancer for which the patient was receiving active treatment.

double blind

15 sites in Brazil